EUVIMEDEUVIMED entdecken
Crossref

Pazopanib therapy for children, adolescents, and young adults with relapsed and refractory sarcomas

Kosuke Tamefusa iD, Hisashi Ishida, Tomohiro Fujiwara, Go Makimoto, Motoharu Ochi, Takahiro Shiwaku, Kaori Fujiwara, Yasuhisa Tatebe, Kana Washio, Masahiro Tabata, Toshifumi Ozaki, Hirokazu Tsukahara

Japanese Journal of Clinical Oncology · 2025

DOI: 10.1093/jjco/hyaf191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Kosuke Tamefusa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan. Hauptthemen laut MEDLINE: Sulfonamides, Pyrimidines, Sarcoma, Neoplasm Recurrence, Local. Die Arbeit nennt 40 Literaturangaben. Gefördert von: JSPS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pazopanib is used to treat relapsed and refractory sarcomas. Pazopanib’s role in pediatric, adolescent, and young adult populations remains unestablished.

Methods

To assess pazopanib’s utility, we analyzed retrospectively collected data from pediatric (0–14 years) and adolescent and young adult (15–39 years) patients diagnosed with relapsed or refractory sarcomas who received pazopanib.

Results

We assessed data from 21 patients (10 pediatric, 11 adolescent, and young adult). Their diagnoses included osteosarcoma (n = 11), rhabdomyosarcoma (n = 4), alveolar soft part sarcoma (n = 5), and leiomyosarcoma (n = 1). Thirteen (62%) patients presented with metastatic disease at the initial diagnosis. Patients had received a median of three prior chemotherapy regimens (range: 0–6). The median duration of pazopanib treatment was 3.5 months (range: 1–12) for pediatric patients and 4 months (range: 1–83) for adolescents and young adults. Nine patients (five adolescents and young adults) discontinued pazopanib owing to disease progression, and two discontinued owing to adverse events (pneumothorax). We observed seven cases of stable disease (four adolescents and young adults) and 12 of progressive disease (six adolescents and young adults) after ~3 months. The median survival following pazopanib initiation was 7.8, 4.8, and 12.4 months for overall, pediatric, and adolescent and young adult patients, respectively.

Conclusions

In a small cohort of children and adolescent and young adult patients with heavily pretreated relapsed or refractory sarcoma, pazopanib may be a feasible option. Further research on optimal therapeutic timing and the target population for pazopanib’s indication is required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulfonamidesPyrimidinesSarcomaNeoplasm Recurrence, LocalAngiogenesis InhibitorsHumansAdolescentIndazolesMaleFemaleYoung AdultAdultChildRetrospective StudiesChild, PreschoolInfantInfant, Newborn

Stichwörter der Autor:innen

adolescentchildpazopanibsarcomayoung adult

Substanzen

pazopanibIndazolesSulfonamidesPyrimidinesAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Pediatrics, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.
  • Department of Orthopedic Surgery, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.
  • Center for Clinical Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.
  • Department of Pharmacy, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.

ORCID-Profile: Kosuke Tamefusa

Förderung

  • JSPS

Zitieren

APA

Tamefusa, K., Ishida, H., Fujiwara, T., Makimoto, G., Ochi, M., Shiwaku, T., Fujiwara, K., Tatebe, Y., Washio, K., Tabata, M., Ozaki, T., & Tsukahara, H. (2025). Pazopanib therapy for children, adolescents, and young adults with relapsed and refractory sarcomas. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf191

Vancouver

Tamefusa K, Ishida H, Fujiwara T, Makimoto G, Ochi M, Shiwaku T, et al. Pazopanib therapy for children, adolescents, and young adults with relapsed and refractory sarcomas. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf191

BibTeX
@article{Tamefusa2025,
  author = {Tamefusa, Kosuke and Ishida, Hisashi and Fujiwara, Tomohiro and Makimoto, Go and Ochi, Motoharu and Shiwaku, Takahiro and Fujiwara, Kaori and Tatebe, Yasuhisa and Washio, Kana and Tabata, Masahiro and Ozaki, Toshifumi and Tsukahara, Hirokazu},
  title = {Pazopanib therapy for children, adolescents, and young adults with relapsed and refractory sarcomas},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1093/jjco/hyaf191}
}
Kostenlos starten →